IONIS PHARMACEUTICALS INC
zilganersen
Alexander disease
Resolved
77days ago
Phase 3 readout · Apr 21, 2026
What's at stake
Phase 3 trial results for zilganersen in Alexander disease are due Apr 21, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Additionally, results from the GMFM-88 in children 2-4 years of age support that zilganersen may improve gross motor function at Week 61 compared to control (least square mean difference 22.9 points, nominal 1 p=0.034).”